{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:03:09Z","timestamp":1791414189189,"version":"4.3.3"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,9]]},"abstract":"ABSTRACT<\/jats:title>\n \n The\n in vitro<\/jats:italic>\n activity of tedizolid (previously known as torezolid, TR-700) against penicillin-resistant\n Streptococcus pneumoniae<\/jats:named-content>\n (PRSP) clinical isolates and the\n in vivo<\/jats:italic>\n efficacy of tedizolid phosphate (torezolid phosphate, TR-701) in murine models of PRSP systemic infection and penicillin-susceptible\n S. pneumoniae<\/jats:named-content>\n (PSSP) pneumonia were examined using linezolid as a comparator. The MIC\n 90<\/jats:sub>\n against 28 PRSP isolates was 0.25 \u03bcg\/ml for tedizolid, whereas it was 1 \u03bcg\/ml for linezolid. In mice infected systemically with a lethal inoculum of PRSP 1 h prior to a single administration of either antimicrobial, oral tedizolid phosphate was equipotent to linezolid (1 isolate) to 2-fold more potent than linezolid (3 isolates) for survival at day 7, with tedizolid phosphate 50% effective dose (ED\n 50<\/jats:sub>\n ) values ranging from 3.19 to 11.53 mg\/kg of body weight\/day. In the PSSP pneumonia model, the ED\n 50<\/jats:sub>\n for survival at day 15 was 2.80 mg\/kg\/day for oral tedizolid phosphate, whereas it was 8.09 mg\/kg\/day for oral linezolid following 48 h of treatment with either agent. At equivalent doses (10 mg\/kg once daily tedizolid phosphate or 5 mg\/kg twice daily linezolid), pneumococcal titers in the lungs at 52 h postinfection were approximately 3 orders of magnitude lower with tedizolid phosphate treatment than with linezolid treatment or no treatment. Lung histopathology showed less inflammatory cell invasion into alveolar spaces in mice treated with tedizolid phosphate than in untreated or linezolid-treated mice. These results demonstrate that tedizolid phosphate is effective in murine models of PRSP systemic infection and PSSP pneumonia.\n <\/jats:p>","DOI":"10.1128\/aac.00346-12","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T13:05:53Z","timestamp":1340283953000},"page":"4713-4717","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Activity of Tedizolid Phosphate (TR-701) in Murine Models of Infection with Penicillin-Resistant and Penicillin-Sensitive Streptococcus pneumoniae"],"prefix":"10.1128","volume":"56","author":[{"given":"Sunghak","family":"Choi","sequence":"first","affiliation":[{"name":"Dong-A Pharmaceutical Co., Yongin-Si, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weonbin","family":"Im","sequence":"additional","affiliation":[{"name":"Dong-A Pharmaceutical Co., Yongin-Si, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Bartizal","sequence":"additional","affiliation":[{"name":"Trius Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3484-3489.2002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01569-09"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/520286"},{"key":"e_1_3_2_5_2","first-page":"1353","article-title":"Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae-\u2013United States, 2006-2007","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. 2008. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae-\u2013United States, 2006-2007. MMWR Morb. Mortal. Wkly. Rep. 57:1353\u20131355.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_6_2","unstructured":"Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. M100-S18. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1475-1480.2002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00502-11"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01729-10"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05354-11"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.04.005"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp267"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2127"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01565-10"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1202939"},{"key":"e_1_3_2_16_2","volume-title":"Approved standard, NCCLS document M7-A5","author":"National Committee for Clinical Laboratory Standards","year":"2000","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, NCCLS document M7-A5, 5th ed, vol 20, no. 2. National Committee for Clinical Laboratory Standards, Wayne, PA.","edition":"5"},{"key":"e_1_3_2_17_2","unstructured":"Pfizer. March 2012 posting date. Zyvox\u00ae prescribing Information. Pfizer New York NY."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00228-09"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06427-11"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00728-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00346-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00346-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:09:31Z","timestamp":1645481371000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00346-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1128\/AAC.00346-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00346-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"2012-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}